Literature DB >> 29527595

Dramatic Response to Crizotinib in a Patient with Lung Cancer Positive for an HLA-DRB1-MET Gene Fusion.

Kurtis D Davies1, Terry L Ng2, Adriana Estrada-Bernal2, Anh T Le2, Peter R Ennever3, D Ross Camidge2, Robert C Doebele2, Dara L Aisner1.   

Abstract

Entities:  

Year:  2017        PMID： 29527595      PMCID： PMC5844276          DOI： 10.1200/PO.17.00117

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN： 2473-4284


× No keyword cloud information.
  22 in total

1.  Impaired c-Met Receptor Degradation Mediated by MET Exon 14 Mutations in Non-Small-Cell Lung Cancer.

Authors:  Mark M Awad
Journal:  J Clin Oncol       Date:  2016-01-19       Impact factor: 44.544

2.  Molecular characteristics of non-small cell lung cancer.

Authors:  M Nacht; T Dracheva; Y Gao; T Fujii; Y Chen; A Player; V Akmaev; B Cook; M Dufault; M Zhang; W Zhang; M Guo; J Curran; S Han; D Sidransky; K Buetow; S L Madden; J Jen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

3.  EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases.

Authors:  Aria Vaishnavi; Laura Schubert; Uwe Rix; Lindsay A Marek; Anh T Le; Stephen B Keysar; Magdalena J Glogowska; Matthew A Smith; Severine Kako; Natalia J Sumi; Kurtis D Davies; Kathryn E Ware; Marileila Varella-Garcia; Eric B Haura; Antonio Jimeno; Lynn E Heasley; Dara L Aisner; Robert C Doebele
Journal:  Cancer Res       Date:  2017-04-20       Impact factor: 12.701

4.  Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Authors:  Garrett M Frampton; Siraj M Ali; Mark Rosenzweig; Juliann Chmielecki; Xinyuan Lu; Todd M Bauer; Mikhail Akimov; Jose A Bufill; Carrie Lee; David Jentz; Rick Hoover; Sai-Hong Ignatius Ou; Ravi Salgia; Tim Brennan; Zachary R Chalmers; Savina Jaeger; Alan Huang; Julia A Elvin; Rachel Erlich; Alex Fichtenholtz; Kyle A Gowen; Joel Greenbowe; Adrienne Johnson; Depinder Khaira; Caitlin McMahon; Eric M Sanford; Steven Roels; Jared White; Joel Greshock; Robert Schlegel; Doron Lipson; Roman Yelensky; Deborah Morosini; Jeffrey S Ross; Eric Collisson; Malte Peters; Philip J Stephens; Vincent A Miller
Journal:  Cancer Discov       Date:  2015-05-13       Impact factor: 39.397

5.  Recurrent MET fusion genes represent a drug target in pediatric glioblastoma.

Authors: 
Journal:  Nat Med       Date:  2016-10-17       Impact factor: 53.440

6.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Authors:  Benjamin J Solomon; Tony Mok; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Shrividya Iyer; Arlene Reisman; Keith D Wilner; Jennifer Tursi; Fiona Blackhall
Journal:  N Engl J Med       Date:  2014-12-04       Impact factor: 91.245

7.  Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.

Authors:  Hyo Sup Shim; Mari- Kenudson; Zongli Zheng; Matthew Liebers; Yoon Jin Cha; Quan Hoang Ho; Maristela Onozato; Long Phi Le; Rebecca S Heist; A John Iafrate
Journal:  J Thorac Oncol       Date:  2015-08       Impact factor: 15.609

8.  Direct observation of individual endogenous protein complexes in situ by proximity ligation.

Authors:  Ola Söderberg; Mats Gullberg; Malin Jarvius; Karin Ridderstråle; Karl-Johan Leuchowius; Jonas Jarvius; Kenneth Wester; Per Hydbring; Fuad Bahram; Lars-Gunnar Larsson; Ulf Landegren
Journal:  Nat Methods       Date:  2006-10-29       Impact factor: 28.547

9.  The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.

Authors:  Jeffrey S Ross; Kai Wang; Juliann Chmielecki; Laurie Gay; Adrienne Johnson; Jacob Chudnovsky; Roman Yelensky; Doron Lipson; Siraj M Ali; Julia A Elvin; Jo-Anne Vergilio; Steven Roels; Vincent A Miller; Brooke N Nakamura; Adam Gray; Michael K Wong; Philip J Stephens
Journal:  Int J Cancer       Date:  2015-09-08       Impact factor: 7.396

10.  Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.

Authors:  Alexander Drilon; Natasha Rekhtman; Maria Arcila; Lu Wang; Andy Ni; Melanie Albano; Martine Van Voorthuysen; Romel Somwar; Roger S Smith; Joseph Montecalvo; Andrew Plodkowski; Michelle S Ginsberg; Gregory J Riely; Charles M Rudin; Marc Ladanyi; Mark G Kris
Journal:  Lancet Oncol       Date:  2016-11-04       Impact factor: 41.316
View more
  22 in total

1.  Tepotinib Efficacy in a Patient with Non-Small Cell Lung Cancer with Brain Metastasis Harboring an HLA-DRB1-MET Gene Fusion.

Authors:  Félix Blanc-Durand; Raafat Alameddine; Anthony J Iafrate; Danh Tran-Thanh; Ying-Chun Lo; Normand Blais; Bertrand Routy; Mustapha Tehfé; Charles Leduc; Phillipe Romeo; Phillipe Stephenson; Marie Florescu
Journal:  Oncologist       Date:  2020-09-08

2.  Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing.

Authors:  Michael Seager; Dara L Aisner; Kurtis D Davies
Journal:  J Vis Exp       Date:  2019-07-05       Impact factor: 1.355

Review 3.  New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1).

Authors:  Alessandro Russo; Ana Rita Lopes; Michael G McCusker; Sandra Gimenez Garrigues; Giuseppina R Ricciardi; Katherine E Arensmeyer; Katherine A Scilla; Ranee Mehra; Christian Rolfo
Journal:  Curr Oncol Rep       Date:  2020-04-16       Impact factor: 5.075

Review 4.  The multiple paths towards MET receptor addiction in cancer.

Authors:  Leslie Duplaquet; Zoulika Kherrouche; Simon Baldacci; Philippe Jamme; Alexis B Cortot; Marie-Christine Copin; David Tulasne
Journal:  Oncogene       Date:  2018-03-19       Impact factor: 9.867

5.  Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer.

Authors:  Sana D Karam; Krishna Reddy; Patrick J Blatchford; Tim Waxweiler; Alicia M DeLouize; Ayman Oweida; Hilary Somerset; Carrie Marshall; Christian Young; Kurtis D Davies; Madeleine Kane; Aik Choo Tan; Xiao Jing Wang; Antonio Jimeno; Dara L Aisner; Daniel W Bowles; David Raben
Journal:  Clin Cancer Res       Date:  2018-07-03       Impact factor: 12.531

Review 6.  MET-dependent solid tumours - molecular diagnosis and targeted therapy.

Authors:  Robin Guo; Jia Luo; Jason Chang; Natasha Rekhtman; Maria Arcila; Alexander Drilon
Journal:  Nat Rev Clin Oncol       Date:  2020-06-08       Impact factor: 66.675

7.  Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.

Authors:  Caroline E McCoach; Anh T Le; Katherine Gowan; Kenneth Jones; Laura Schubert; Andrea Doak; Adriana Estrada-Bernal; Kurtis D Davies; Daniel T Merrick; Paul A Bunn; W Tom Purcell; Rafal Dziadziuszko; Marileila Varella-Garcia; Dara L Aisner; D Ross Camidge; Robert C Doebele
Journal:  Clin Cancer Res       Date:  2018-04-10       Impact factor: 12.531

8.  Identification of a Novel EHBP1-MET Fusion in an Intrahepatic Cholangiocarcinoma Responding to Crizotinib.

Authors:  Yiyi Yu; Qing Liu; Wei Li; Yueting Qu; Yihong Zhang; Tianshu Liu
Journal:  Oncologist       Date:  2020-10-12

9.  Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples.

Authors:  Kurtis D Davies; Anh T Le; Jamie Sheren; Hala Nijmeh; Katherine Gowan; Kenneth L Jones; Marileila Varella-Garcia; Dara L Aisner; Robert C Doebele
Journal:  J Thorac Oncol       Date:  2018-06-20       Impact factor: 15.609

10.  Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in KRAS Wild-Type Pancreatic Cancer.

Authors:  Michael J Fusco; Daryoush Saeed-Vafa; Estrella M Carballido; Theresa A Boyle; Mokenge Malafa; Kirsten L Blue; Jamie K Teer; Christine M Walko; Howard L McLeod; J Kevin Hicks; Martine Extermann; Jason B Fleming; Todd C Knepper; Dae Won Kim
Journal:  JCO Precis Oncol       Date:  2021-01-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.